1. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Issue 10075 (25th March 2017) Authors: Cameron, David; Piccart-Gebhart, Martine J; Gelber, Richard D; Procter, Marion; Goldhirsch, Aron; de Azambuja, Evandro; Castro, Gilberto; Untch, Michael; Smith, Ian; Gianni, Luca; Baselga, Jose; Al-Sakaff, Nedal; Lauer, Sabine; McFadden, Eleanor; Leyland-Jones, Brian; Bell, Richard; Dowsett, Mitc... Journal: Lancet Issue: Volume 389:Issue 10075(2017) Page Start: 1195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Issue 6 (November 2016) Authors: Abramovitz, Mark; Krie, Amy; Dey, Nandini; De, Pradip; Williams, Casey; Leyland-Jones, Brian Journal: Current opinion in oncology Issue: Volume 28:Issue 6(2016:Nov.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Issue 6 (November 2016) Authors: Abramovitz, Mark; Krie, Amy; Dey, Nandini; De, Pradip; Williams, Casey; Leyland-Jones, Brian Journal: Current opinion in oncology Issue: Volume 28:Issue 6(2016:Nov.) Page Start: 461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer. Issue 4 (16th August 2019) Authors: Buechler, Steven A; Gray, Kathryn P; Gökmen-Polar, Yesim; Willis, Scooter; Thürlimann, Beat; Kammler, Rosita; Viale, Giuseppe; Leyland-Jones, Brian; Badve, Sunil S; Regan, Meredith M Journal: JNCI cancer spectrum Issue: Volume 3:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. (10th August 2021) Authors: Bossuyt, Veerle; Lau, Rosanna; Young, Brandon; Howe, John Greg; Zhao, Fengmin; Leyland-Jones, Brian; Du, Lili; Foli, Tiffany; Hatzis, Christos; Symmans, W Fraser Journal: Clinical chemistry Issue: Volume 67:Number 9(2021) Page Start: 1240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Mutation matters in precision medicine: A future to believe in. (April 2017) Authors: Dey, Nandini; Williams, Casey; Leyland-Jones, Brian; De, Pradip Journal: Cancer treatment reviews Issue: Volume 55(2017) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. (March 2008) Authors: Abramovitz, Mark; Ordanic-Kodani, Maja; Wang, Yuefang; Li, Zhenhong; Catzavelos, Charles; Bouzyk, Mark; Sledge, George W.; Moreno, Carlos S.; Leyland-Jones, Brian Journal: Biotechniques Issue: Volume 44:Number 3(2008) Page Start: 417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pharmacogenetics of breast cancer : towards the individualization of therapy /: towards the individualization of therapy. (2020) Editors: Leyland-Jones, Brian Record Type: Book Extent: 1 online resource View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PI3K-mTOR in cancer and cancer therapy. (2016) Editors: Dey, Nandini; De, Pradip; Leyland-Jones, Brian Record Type: Book Extent: 1 online resource (xxiv, 294 pages), color illustrations View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Issue 1 (January 2022) Authors: Yau, Christina; Osdoit, Marie; van der Noordaa, Marieke; Shad, Sonal; Wei, Jane; de Croze, Diane; Hamy, Anne-Sophie; Laé, Marick; Reyal, Fabien; Sonke, Gabe S; Steenbruggen, Tessa G; van Seijen, Maartje; Wesseling, Jelle; Martín, Miguel; del Monte-Millán, Maria; López-Tarruella, Sara; Boughey, Ju... Journal: Lancet oncology Issue: Volume 23:Issue 1(2022) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗